Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other brokerages have also commented on RVPH. Chardan Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. D. Boral Capital reissued a “buy” rating and set a $2.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Wednesday, October 8th. Finally, Benchmark decreased their price objective on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a research note on Monday, September 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $3.86.

Reviva Pharmaceuticals Stock Performance

RVPH opened at $0.31 on Friday. Reviva Pharmaceuticals has a 1 year low of $0.25 and a 1 year high of $2.17. The company’s 50 day simple moving average is $0.55 and its 200 day simple moving average is $0.51. The stock has a market capitalization of $35.31 million, a PE ratio of -0.67 and a beta of -0.02.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. As a group, sell-side analysts expect that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC increased its stake in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares during the period. Lido Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals during the third quarter valued at about $37,000. 683 Capital Management LLC purchased a new stake in shares of Reviva Pharmaceuticals during the second quarter worth about $381,000. Armistice Capital LLC purchased a new stake in shares of Reviva Pharmaceuticals during the second quarter worth about $1,026,000. Finally, XTX Topco Ltd acquired a new position in shares of Reviva Pharmaceuticals in the second quarter worth about $31,000. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.